TransMedics GroupTMDX
Recorded

TransMedics Group 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Tom StephanVP of Healthcare Equity Research

Okay. Morning, everyone. Tom Stephan with Stifel Research. Really excited to have TransMedics at the conference this year for the first time. Waleed, Fernando, thanks so much for joining.

Tom StephanVP of Healthcare Equity Research

Thank you. I am going to jump right into Q&A, and I will start things off away from liver, and I will start on heart and lung.

Tom StephanVP of Healthcare Equity Research

Big picture question to kick things off, Waleed, maybe for you. OCS's presence in liver, it has grown quickly. Heart and lung, relatively speaking, have lagged. Maybe to start, Waleed, can you talk about the challenges of the heart and the lung markets more broadly? I guess more specifically, how should OCS 2.0 address those challenges and help you compete more effectively?

Waleed HassaneinFounder, President, and CEO

Sure. First, Tom, thank you for the invite to be here. We are excited to be at your conference this year. I wouldn't call it challenges of the heart and lung as much as it is just that there is a different market dynamic in cardiothoracic versus liver. Liver have dedicated teams that do nothing but liver transplant. They do not do any other type of surgery. Heart and lung, they are busy doing regular open heart surgery, valve surgery, cancer surgery in the case of the lung. That is an inherent dynamic of the market. Also, the machine perfusion started in heart and lung first before it came to liver. So it is a busier market, a crowded market.

Waleed HassaneinFounder, President, and CEO

For us, we always knew that we need to go back and tackle heart and lung in a systematic way, but we were rapidly deploying OCS across the liver market, and the impact of OCS in liver is just, it's a game changer, and that's why we wanted to capitalize on that opportunity. But we now, with the OCS 2.0, we are able to systematically address some key areas that we know historically have caused a little bit of consternation in the heart and lung users. The area of, does the organ become edematous because of perfusion, which may compromise the post-transplant outcomes? Could we really keep the organs overnight on OCS like the liver guys are doing morning hour transplant? Could we enhance the organ function over time versus just suspended animation or preserving the organ at its current state?

Waleed HassaneinFounder, President, and CEO

We came up with a comprehensive set of enhancers and technology innovation in 2.0, and we're very, very excited about where we are and what we've seen in ENHANCE Part A is a very rapid adoption in the trial. We closed the trial, 175 patients, effectively in seven or eight months, which is one of the most fastest enrolling trial we've ever conducted. That's usually, at least our internal metric, it's usually a good sign to tell us that the technology is delivering on the promise. And we hope to replicate that in Part B and DENOVO. We couldn't be more excited about what these two clinical programs could potentially do. At a very high level, if they succeed, that would give us access to approximately 5,000 to 5,500 new cases every year in the United States.

Waleed HassaneinFounder, President, and CEO

That's between 3,500 lungs and 2,200 hearts that today we don't access routinely.

Tom StephanVP of Healthcare Equity Research

Okay, great. Super helpful. And I think your point about cardiothoracic surgeons, different priorities, I think that's an interesting one where, as we think about daytime transplantation and 2.0, and heart potentially opening that up, does the different priorities, the variety of priorities of these surgeons, as well as probably OR constraints, since they're doing a lot of different procedures, does that possibly lessen the importance of 2.0 opening up daytime transplantation in heart or no?

Waleed HassaneinFounder, President, and CEO

Yeah. The opening up of daytime transplantation in heart is the least of our concern. It is a nice to have. The number one priority for us for ENHANCE Part B and DENOVO is to deliver a better organ transplant in heart and lungs, to increase utilization of donor hearts and donor lungs into transplant. These are the fundamental game-changing impact of 2.0. Whether or not it results in a daytime transplant, it is really up to the market to adopt that at their own pace. But for us, we are focusing primarily on the outcomes and the ability to access this very, very important market segment that we just historically didn't access.

Tom StephanVP of Healthcare Equity Research

Got it. Maybe digging into ENHANCE Part B a little bit. For DBD hearts with sub-four-hour preservation, that incremental market you are targeting, arguably it is a, I have in quotes, "easier heart" on a relative basis. So what is the bar for 2.0 to show clinical superiority to static cold storage? Maybe as we think about survival rates, severe PGD rates, I could probably look up the literature, but what is the bar where it feels like it could be high? Talk about what 2.0 will have to show to exhibit superiority in that subgroup of hearts?

Waleed HassaneinFounder, President, and CEO

Yeah. We are tackling that very important questions from two angles. The first angle is, we designed the trial to have a primary effectiveness endpoint that combines severe PGD and survival. These are the two gold standard metrics by which an organ transplant is measured by. So that is number one. Number two, we are comparing ourselves to another product that has clear, better capabilities than just a Styrofoam box with a phase-changing material, which is CHOPS. So for us, achieving superiority is what we hope to achieve because we believe that OCS warm, OCS oxygenated perfusion, and with the enhancers should deliver superior outcomes. But even if that doesn't happen or if it happens, but the transplant surgeon or team would like to use cold storage, CHOPS comes into play. So for us, we really, as I said, we couldn't be more excited about where we are.

Waleed HassaneinFounder, President, and CEO

We have two tigers by the tail. We have technology that we believe should deliver superior outcomes for transplantation, increased utilization for transplantation. But if the transplant surgeon or teams would like to use cold storage, we are giving them a better cold storage technique than just a Styrofoam box with phase-changing material. So, in both case, I believe TransMedics is in good place to capitalize on this opportunity.

Tom StephanVP of Healthcare Equity Research

Okay. Fantastic. And then maybe last one here on heart and lung. For the OCS volumes in DENOVO and ENHANCE Part B, DENOVO we can sort of think about all OCS within that as incremental since you're relatively small there. But on ENHANCE Part B, how much of the 400 OCS will be truly incremental volume? Is it all 100%. 100%.

Waleed HassaneinFounder, President, and CEO

Actually, I would argue all 600 cases, the 400 OCS Right and the 200 on CHOPS, these are all incremental because that is an indication that we currently don't have in the U.S.

Tom StephanVP of Healthcare Equity Research

Got it. That's very helpful. In total, between DENOVO and the incremental volumes in ENHANCE Part B, I think DENOVO is 300 OCS and 100 150 and 150- 150 CHOPS.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day